Compare Nvidia Corp (NVDA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs BIO-TECHNE Corp — how do they compare? Nvidia Corp trades at $229.28 (market cap $5.57T), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Nvidia Corp is far larger — about 490.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and BIO-TECHNE Corp for 64 Days on average.
| NVDA | TECH | |
|---|---|---|
Market Cap | $5.57T | $11.36B |
Volume | 117,720,595 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $239.27 | $72.61 |
52-Week Low | $165.17 | $43.31 |
Typical Hold Time | 115 Days | 64 Days |
Enterprise Value | $5.54T | $11.39B |
Dividend Yield | 0.43% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $230.48, down 2.9% on the day, with strong technical support at $228 and resistance at $235. The company demonstrates exceptional fundamental strength with 2025 revenue of $130.5B and net income of $72.9B, achieving a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 exceeding the $2.09 forecast. Analyst consensus remains strongly bullish with a $339.17 price target representing 47% upside potential from current levels.
NVIDIA's AI leadership and accelerating revenue growth position it for continued outperformance, though investors face risks from increased competition and market volatility. The stock's current valuation metrics (P/E 29.14, P/S 18.56) reflect premium pricing justified by exceptional profitability and market dominance in AI infrastructure. Institutional sentiment remains positive despite recent profit-taking by some funds.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, as the stock approaches its 52-week high of $72.70. The company shows strong profitability with 65.77% gross margins and 14.97% net income margin, though earnings have been mixed with one miss and two beats in recent quarters. Technical indicators show a bullish trend with support at $72 and resistance at $73. Recent news highlights shareholder approval of the Merck KGaA acquisition at $73 per share, providing a clear near-term catalyst.
The acquisition premium offers limited upside from current levels, while fundamental metrics show elevated valuation (P/E 62.46) despite solid profitability. Key risks include integration challenges post-acquisition and potential regulatory scrutiny. Analyst consensus leans neutral with 46% buy ratings and a $65.78 price target below current trading levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
